AU2016294526A1 - Transpapillary methods and compositions for treating breast disorders - Google Patents

Transpapillary methods and compositions for treating breast disorders Download PDF

Info

Publication number
AU2016294526A1
AU2016294526A1 AU2016294526A AU2016294526A AU2016294526A1 AU 2016294526 A1 AU2016294526 A1 AU 2016294526A1 AU 2016294526 A AU2016294526 A AU 2016294526A AU 2016294526 A AU2016294526 A AU 2016294526A AU 2016294526 A1 AU2016294526 A1 AU 2016294526A1
Authority
AU
Australia
Prior art keywords
composition
breast
carcinoma
nipple
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016294526A
Other languages
English (en)
Inventor
Steven C. Quay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Atossa Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Genetics Inc filed Critical Atossa Genetics Inc
Publication of AU2016294526A1 publication Critical patent/AU2016294526A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016294526A 2015-07-14 2016-07-14 Transpapillary methods and compositions for treating breast disorders Abandoned AU2016294526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192505P 2015-07-14 2015-07-14
US62/192,505 2015-07-14
PCT/US2016/042202 WO2017011623A1 (en) 2015-07-14 2016-07-14 Transpapillary methods and compositions for treating breast disorders

Publications (1)

Publication Number Publication Date
AU2016294526A1 true AU2016294526A1 (en) 2018-02-08

Family

ID=57757662

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016294526A Abandoned AU2016294526A1 (en) 2015-07-14 2016-07-14 Transpapillary methods and compositions for treating breast disorders

Country Status (7)

Country Link
US (1) US20180200206A1 (cg-RX-API-DMAC7.html)
EP (1) EP3322406A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018520182A (cg-RX-API-DMAC7.html)
CN (1) CN108024959A (cg-RX-API-DMAC7.html)
AU (1) AU2016294526A1 (cg-RX-API-DMAC7.html)
CA (1) CA2992282A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017011623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3283061A4 (en) * 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES
EP3679061A4 (en) * 2017-09-06 2021-06-09 University of Cincinnati METHOD OF PREDICTING BREAST LESIONS IN EARLY STAGE
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
CN110221068B (zh) * 2018-03-02 2020-09-18 中国医学科学院基础医学研究所 检测Kyn含量的试剂的应用
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
US6398765B1 (en) * 1999-03-01 2002-06-04 Pro Duct Health, Inc. Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts
US20020117169A1 (en) * 2001-02-27 2002-08-29 Kurz Daniel R. Cover and applicator for a portion of a mammalian body
JP2004530659A (ja) * 2001-02-28 2004-10-07 ジャイルズ,ブライアン,シー. 抗腫瘍および抗転移作用のための方法および処方
DE60322191D1 (de) * 2002-03-19 2008-08-28 Cytyc Corp Intraduktale behandlung von brustläsionen umfassend therapeutische und diagnostische mittel
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
KR100419298B1 (ko) * 2003-07-28 2004-02-18 조규학 부착형 브래지어 및 그 제조방법
US7229420B2 (en) * 2003-12-23 2007-06-12 Cytyc Corporation Medical instrument for accessing a breast duct for performing a medical procedure
US20050142315A1 (en) * 2003-12-24 2005-06-30 Desimone Joseph M. Liquid perfluoropolymers and medical applications incorporating same
IL177006A0 (en) * 2005-08-02 2006-12-10 Veridex Llc Predicting bone relapse of breast cancer
WO2007067773A2 (en) * 2005-12-09 2007-06-14 Mayo Foundation For Medical Education And Research Assessing outcomes for breast cancer patients by determining cyp2d6 genotype
ES2539042T3 (es) * 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Procedimiento de identificación de si un paciente será respondedor o no a inmunoterapia
PT2101731T (pt) * 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
WO2009105640A1 (en) * 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
WO2010008427A1 (en) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Tryptophan catabolism in cancer treatment and diagnosis
WO2009129352A2 (en) * 2008-04-15 2009-10-22 Windy Hill Medical Device and method for accessing and treating ducts of mammary glands
WO2010009335A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
ES2624557T3 (es) * 2008-12-11 2017-07-14 Besins Healthcare Luxembourg Sarl Composiciones farmacéuticas transdérmicas que comprenden un SERM
WO2011072244A1 (en) * 2009-12-10 2011-06-16 Mount Sinai School Of Medicine Of New York University Method of treatment of breast cancer with tamoxifen
EP2425833A1 (de) * 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
US20130045179A1 (en) * 2011-08-15 2013-02-21 Mihai Ciustea Combination therapy and methods for treatment and prevention of hyperproliferative diseases
US9517183B2 (en) * 2012-01-30 2016-12-13 Patrick B. Ward Nipple abrasion protector
WO2013134230A1 (en) * 2012-03-05 2013-09-12 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
US9220680B2 (en) * 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
EP3092027A4 (en) * 2014-01-10 2017-09-06 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
EP3283061A4 (en) * 2015-04-14 2019-04-17 Atossa Genetics Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF BREAST DISEASES AND ORGANISM-RELATED ILLNESSES

Also Published As

Publication number Publication date
JP2018520182A (ja) 2018-07-26
EP3322406A1 (en) 2018-05-23
WO2017011623A1 (en) 2017-01-19
CN108024959A (zh) 2018-05-11
CA2992282A1 (en) 2017-01-19
US20180200206A1 (en) 2018-07-19
EP3322406A4 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
EP3322406A1 (en) Transpapillary methods and compositions for treating breast disorders
Carlson et al. Invasive breast cancer
Rizzoli et al. Cancer-associated bone disease
Robertson et al. Inflammatory breast cancer: the disease, the biology, the treatment
Vitolo et al. Primary testicular lymphoma
Brown et al. Denosumab in patients with cancer—a surgical strike against the osteoclast
Moncayo et al. Status of sentinel lymph node for breast cancer
Kataja et al. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
Park-Simon et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2025
US20160375234A1 (en) Transpapillary methods and compositions for diagnosing and treating breast conditions
EP4069218A1 (en) Combination therapies for treatment of breast cancer
Theivendren et al. The future perspectives of drug repurposing and treatment for the drug resistant breast cancer
Somashekhar et al. Association of Breast Surgeons of India (ABSI) practical consensus statement, recommendations, and guidelines for the treatment of breast cancer in India 2021—Indian solutions for Indian problems
Kaufmann et al. Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer
HK1255302A1 (en) Transpapillary methods and compositions for treating breast disorders
Tewari et al. Breast Cancer: A Global Burden
Dietl et al. FDG-PET in radiotherapy treatment planning of advanced head and neck cancer—a prospective clinical analysis
Sharma et al. Recent development in treatment strategies for breast cancer: With special reference to immunotherapy
Breast Cancer Expert Committee of the National Quality Control Center for Cancer et al. Guidelines for the Diagnosis and Treatment of Advanced Breast Cancer in China (2024 Edition)
Kawahara et al. Ovarian apocrine carcinoma arising from a mature cystic teratoma: a case report.
PeaceHealth et al. Breast Cancer Treatment (PDQ®): Treatment-Health Professional Information [NCI]
Hu et al. Effect of cisplatin arterial infusion (CAI) on primary nonmetastatic pelvic osteosarcoma: a preliminary study
Imai et al. Primary non-Hodgkin’s malignant lymphoma of the breast: long-term follow-up
Chin Advancing Surgical Strategies for Breast Cancer in the Era of Neoadjuvant Chemotherapy
Simeone Pain and analgesic use associated with sres in patients with advanced breast cancer and bone metastases treated with bone-modifying agents: a retrospective observational study